Stock of the Day

February 10, 2023

Vera Therapeutics (VERA)

$28.57
+$1.83 (+6.8%)
Market Cap: $1.93B

About Vera Therapeutics

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Today's Trend

Vera Therapeutics, Inc. (NASDAQ: VERA) shares have increased as investors assess encouraging late-stage data for TRUTAKNA (atacicept), the company’s lead candidate for immunoglobulin A nephropathy (IgAN).

  • Phase 3 success supports approval hopes: Vera said TRUTAKNA met all primary and secondary endpoints in the ORIGIN 3 trial. The results showed sustained kidney protection over two years and a reduction in the decline of kidney function, strengthening the case for full approval in IgAN. Vera Therapeutics says TRUTAKNA met all Phase III endpoints
  • Commercial opportunity is improving: The favorable ORIGIN 3 data could position TRUTAKNA for broader use in IgAN and intensify competition with other kidney-disease treatments, including products developed by Otsuka. Investors viewed the durable efficacy and kidney-function benefits as important differentiators. Vera’s strong Phase 3 IgAN data intensify kidney disease rivalry
  • Investors remain focused on execution: Positive trial results have increased expectations for regulatory approval and eventual commercialization, but some commentary remains cautious about approval timing, launch execution and competition. Vera Therapeutics: Why I’m sticking with Hold despite positive TRUTAKNA data
  • CEO reduced his holdings: CEO Marshall Fordyce sold 18,500 shares for approximately $684,500, reducing his ownership by 7.29%. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which limits its usefulness as a signal about management’s current outlook, but insider selling may still weigh modestly on sentiment. Vera Therapeutics CEO Form 4 filing
← Previous Stock of the DayNext Stock of the Day →

Recent News